SLC5A2 and chronic kidney disease: Moreover, kidney-protective therapies with CV benefits such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, SGLT2 inhibitors, finerenone (non-steroidal mineralocorticoid receptor antagonist) and semaglutide (GLP-1 agonist), should be considered in people with DFU and CKD [132, 148–152].